Stock 301201 CHENGDA PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News ChengDa Pharmaceuticals Co., Ltd.

Equities

301201

CNE100005766

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 08/05/2024 BST 		5-day change 1st Jan Change
22.68 CNY +3.00% Intraday chart for ChengDa Pharmaceuticals Co., Ltd. +12.22% -10.81%
04-21 ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-01 Tranche Update on ChengDa Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on January 9, 2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tranche Update on ChengDa Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on January 9, 2024.
CI
Certain A Shares of ChengDa Pharmaceuticals Co., Ltd. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.
CI
ChengDa Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.
CI
ChengDa Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.
CI
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
ChengDa Pharmaceuticals Co., Ltd.(XSEC:301201) added to S&P Global BMI Index
CI
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023
CI
Chengda Pharmaceuticals Co., Ltd. Announces Directorate Appointments
CI
Chengda Pharmaceuticals Co., Ltd. Approves for the Year 2022
CI
Chengda Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for 2022
CI
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Certain A Shares of ChengDa Pharmaceuticals Co., Ltd. are subject to a Lock-Up Agreement Ending on 20-JAN-2023.
CI
One Gene announced that it has received funding from ChengDa Pharmaceuticals Co., Ltd.
CI
Hangzhou 1gene Technology Co., Ltd. announced that it has received CNY 19.48156 million in funding from ChengDa Pharmaceuticals Co., Ltd.
CI
Hangzhou 1gene Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from ChengDa Pharmaceuticals Co., Ltd.
CI
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
ChengDa Pharmaceuticals to Free Up 1.29% Stake For Trading
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 301201 Stock
  4. News ChengDa Pharmaceuticals Co., Ltd.